Two medicines, side by side
Bupropion vs citalopram
Bupropion and citalopram are both labeled for depression. Drugs@FDA records approvals of bupropion since 1985 and of citalopram since 1998. Pharmacies paid $0.0785 per bupropion HCl xl 150 mg tablet and $0.026 per citalopram hbr 10 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, bupropion is an aminoketone and citalopram a serotonin reuptake inhibitor.
Check it at the source: the bupropion FDA label on DailyMed (effective June 21, 2024); the citalopram FDA label on DailyMed (effective October 9, 2023).
Highlights of the bupropion record
Bupropion (Wellbutrin) · label of June 21, 2024
SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older [see Warnings and Precautions (5.1)].
Used for
From the label: indicationsBupropion hydrochloride extended-release tablets (SR) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD [see Clinical Studies (14)]. […]
On the market
- Earliest approval on file
- December 30, 1985
- Generic labelers
- 69 labelers
- Pharmacy cost
- $0.0785 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 35
Highlights of the citalopram record
Citalopram (Celexa) · label of October 9, 2023
SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short -term studies. Closely m onitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )]. CELEXA is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )].
Used for
From the label: indicationsCELEXA is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. CELEXA is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ).
On the market
- Earliest approval on file
- July 17, 1998
- Generic labelers
- 35 labelers
- Pharmacy cost
- $0.026 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 5
Source: FDA drug labels via openFDA (Bupropion label of June 21, 2024, Citalopram label of October 9, 2023); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do bupropion and citalopram differ on the record?
In FDA's classes, bupropion is an aminoketone and citalopram a serotonin reuptake inhibitor.
How each works, in its label's words: Bupropion, “The exact mechanism of the antidepressant action of bupropion is not known, but is presumed to be related to noradrenergic and/or dopaminergic mechanisms.”; Citalopram, “The mechanism of action of citalopram is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS …”
Half-life, in each label's words: Bupropion, “The mean elimination half-life (±SD) of bupropion after chronic dosing is 21 (±9) hours, and steady-state plasma …”; Citalopram, “Biotransformation of citalopram is mainly hepatic, with a mean terminal half-life of about 35 hours.”
Both labels carry a boxed warning; the records quote them.
Generics: bupropion since 1999; citalopram since 2004 (Drugs@FDA).
| Bupropion | Citalopram | |
|---|---|---|
| Labeled for | Depression, Quitting smoking | Depression |
| Pharmacologic class | Aminoketone | Serotonin Reuptake Inhibitor |
| How it works (label) | The exact mechanism of the antidepressant action of bupropion is not known, but is presumed to be related to noradrenergic and/or dopaminergic mechanisms. | The mechanism of action of citalopram is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). |
| Half-life (label) | The mean elimination half-life (±SD) of bupropion after chronic dosing is 21 (±9) hours, and steady-state plasma concentrations of bupropion are reached within 8 days. | Biotransformation of citalopram is mainly hepatic, with a mean terminal half-life of about 35 hours. |
| Earliest approval on file (Drugs@FDA) | December 30, 1985 | July 17, 1998 |
| First generic approved | November 29, 1999 | October 28, 2004 |
| Generic labelers (NDC) | 69 labelers | 35 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.0785 per tablet (Bupropion HCl xl 150 mg tablet) | $0.026 per tablet (Citalopram hbr 10 mg tablet) |
| 12-month price change | -21% | +6% |
| Boxed warning | Yes | Yes |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 35 | 5 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 140,269 | 136,040 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Citalopram label, drug interactionsConcomitant use of CELEXA and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort) increases the risk of serotonin syndrome.
Source: FDA drug labels via openFDA
What next?
- Alternatives to bupropion
- every medicine labeled for the same conditions